Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients With WHIM Syndrome With Open-Label Extension

NCT03995108 is registered in ClinicalTrials.gov with X4 Pharmaceuticals as lead sponsor.

NCT NCT03995108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03995108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients With WHIM Syndrome With Open-Label Extension
Lead sponsor
X4 Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
October 24, 2019
Completion date
December 23, 2025
Enrollment
31 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

whim syndrome